Using (1,3)-β-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by Madurella mycetomatis

By Nyuykonge B, Siddig EE, Nyaoke BA, Zijlstra EE, Verbon A, Bakhiet SM,  Fahal AH,  van de Sande WWJ. Mycoses 2023, 00:1-8. doi: doi.org/10.1111/myc.13664

Summary: (1,3)-β-D-glucan is a panfungal biomarker present in serum of patients with eumycetoma. In this study, the authors used the WAKO (1,3)-β-D-glucan assay to measure (1,3)-β-D-glucan concentrations in the serum of 104 patients with eumycetoma who were enrolled in a clinical trial of two regimens of the potential eumycetoma treatment fosravuconazole. A sharp decrease in β-glucan concentration was noted after surgical removal of lesions at six months, but not during or after antimicrobial treatment. (1,3)-β-D-glucan concentrations were not predictive for recurrence and do not appear to be of use in determining treatment response to azoles in patients with eumycetoma.

The post Using (1,3)-β-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by Madurella mycetomatis first appeared on DNDi.